Cargando…

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali

Background. In 2010, Africa's first preventive meningococcal mass vaccination campaign was launched using a newly developed Neisseria meningitidis group A (NmA) polysaccharide–tetanus toxoid conjugate vaccine, PsA-TT (MenAfriVac), designed specifically for the meningitis belt. Given PsA-TT'...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basta, Nicole E., Borrow, Ray, Berthe, Abdoulaye, Dembélé, Awa Traoré Eps, Onwuchekwa, Uma, Townsend, Kelly, Boukary, Rahamatou M., Mabey, Lesley, Findlow, Helen, Bai, Xilian, Sow, Samba O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639504/ https://www.ncbi.nlm.nih.gov/pubmed/26553687 http://dx.doi.org/10.1093/cid/civ602

Ejemplares similares

Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali
por: Basta, Nicole E., et al.
Publicado: (2015)

Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso
por: Tall, Haoua, et al.
Publicado: (2015)

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination
por: Holme, Daniel, et al.
Publicado: (2015)

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali
por: Vannice, Kirsten S., et al.
Publicado: (2015)

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials
por: Idoko, Olubukola T., et al.
Publicado: (2015)

Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
por: Diomandé, Fabien V. K., et al.
Publicado: (2015)

Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
por: Tapia, Milagritos D., et al.
Publicado: (2015)

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
por: Diallo, Aldiouma, et al.
Publicado: (2015)

Public Health Impact After the Introduction of PsA-TT: The First 4 Years
por: Diomandé, Fabien V. K., et al.
Publicado: (2015)

The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana
por: Wak, George, et al.
Publicado: (2015)

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014
por: Djingarey, Mamoudou H., et al.
Publicado: (2015)

Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
por: Roy Chowdhury, Panchali, et al.
Publicado: (2015)

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
por: Tang, Yuxiao, et al.
Publicado: (2015)

MenAfriVac as an Antitetanus Vaccine
por: Borrow, Ray, et al.
Publicado: (2015)

Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa
por: Okwo-Bele, Jean-Marie, et al.
Publicado: (2015)

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
por: Tapia, Milagritos D., et al.
Publicado: (2015)

Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine
por: Martellet, Lionel, et al.
Publicado: (2015)

A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa
por: Sambo, Luis, et al.
Publicado: (2015)

Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries
por: Dellepiane, Nora, et al.
Publicado: (2015)

Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
por: Berlier, Monique, et al.
Publicado: (2015)

Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India
por: Kulkarni, Prasad S., et al.
Publicado: (2015)

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
por: Karachaliou, Andromachi, et al.
Publicado: (2015)

Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons
por: Enwere, Godwin C., et al.
Publicado: (2015)

From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project
por: Aguado, M. Teresa, et al.
Publicado: (2015)

The Evolution of the Meningitis Vaccine Project
por: Tiffay, Kathleen, et al.
Publicado: (2015)

Technical Development of a New Meningococcal Conjugate Vaccine
por: Frasch, Carl E., et al.
Publicado: (2015)

Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004–2013
por: Lingani, Clément, et al.
Publicado: (2015)

Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
por: Colombini, Anaïs, et al.
Publicado: (2015)

Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool
por: Cibrelus, Laurence, et al.
Publicado: (2015)

Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys
por: Kaboré, Lassané, et al.
Publicado: (2021)

Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator
por: Sow, Samba O., et al.
Publicado: (2017)

Real-world impact and effectiveness of MenACWY-TT
por: Villena, Rodolfo, et al.
Publicado: (2023)

Decline in Vaccine-Type Streptococcus pneumoniae Serotypes Following Pneumococcal Conjugate Vaccine Introduction in Madagascar
por: Raboba, Julia L, et al.
Publicado: (2021)

Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal
por: Shrestha, Sonu, et al.
Publicado: (2021)

Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic
por: Dunn, Maria G, et al.
Publicado: (2021)

The Burden of Invasive Bacterial Disease and the Impact of 10-Valent Pneumococcal Conjugate Vaccine in Children <5 years hospitalized for Meningitis in Lusaka, Zambia, 2010–2019
por: Yamba, Kaunda, et al.
Publicado: (2021)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Characteristics of patients receiving allergy vaccination: to which extent do socio-economic factors play a role?
por: Petersen, Karin Dam, et al.
Publicado: (2011)

Implications of Differential Age Distribution of Disease-Associated Meningococcal Lineages for Vaccine Development
por: Brehony, Carina, et al.
Publicado: (2014)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vlajg87o375mr1v85cmacugu1r